Aptamer

RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)

Retrieved on: 
Tuesday, December 5, 2023
Health, Communications, Clinical Trials, Pharmaceutical, Publishing, Optical, Biotechnology, Yoshi, Intravitreal injection, Safety, Visual acuity, Retina, Royal college, Anatomy, Risk, Exudate, Anti-VEGF, FGF2, Patient, P, Choroidal neovascularization, Aptamer, Eye, Therapy, Blood, Growth factor, Royal College of Ophthalmologists, Paratriathlon, NAMD, SUSHI, Fibrosis, Pharmaceutical industry, D.S

TEMPURA is an investigator-sponsored, single-center, open-label, 4-month study of umedaptanib pegol in five treatment-naïve nAMD patients.

Key Points: 
  • TEMPURA is an investigator-sponsored, single-center, open-label, 4-month study of umedaptanib pegol in five treatment-naïve nAMD patients.
  • Throughout these studies umedaptanib pegol was safe, well tolerated, and effective to treat nAMD patients with no or short history of anti-VEGF treatment.
  • In nAMD patients with a long history of anti-VEGF treatment, umedaptanib pegol showed no additional benefit of monotherapy or the combination over Eylea®.
  • Notably, visual acuity decreased slightly in patients who switched from anti-VEGF (Eylea®) to umedaptanib pegol in the RAMEN study.

EQS-News: Berlin Cures takes next step in battle against Long COVID

Retrieved on: 
Tuesday, October 17, 2023
Partnership, FAAB, Aptamer, Recovery, Education, COVID, BMBF, Safety, Biotechnology, Phase, Uniklinikum Aachen, German, Patient, Federal Ministry of Health (Germany), Pharmaceutical industry, Long COVID, Research

Berlin, Germany, 10 October 2023 – Berlin Cures, a biotechnology firm specializing in the neutralization of functional autoantibodies (fAABs), is extending its collaboration with Uniklinikum Erlangen in the fight against Long COVID.

Key Points: 
  • Berlin, Germany, 10 October 2023 – Berlin Cures, a biotechnology firm specializing in the neutralization of functional autoantibodies (fAABs), is extending its collaboration with Uniklinikum Erlangen in the fight against Long COVID.
  • This partnership represents a significant step forward in the development of BC 007, Berlin Cures’ leading drug candidate for treating Long COVID and other autoimmune diseases.
  • As an accredited research center for Long COVID, Uniklinikum Erlangen will help Berlin Cures compile significant data on the efficacy and safety of BC 007 for patients with Long COVID.
  • Additionally, we are thrilled to be part of Berlin Cures' Phase II clinical trial, BLOC.”

Stonegate Healthcare Partners Announces Publishing of a Thematic Report - The RNA Revolution: Unleashing the Therapeutic Potential of RNAi

Retrieved on: 
Thursday, July 13, 2023
Ionis, Alnylam Pharmaceuticals, SHP, RNA interference, Therapy, Aptamer, RNA, RNA therapeutics, Messenger, Pharmaceutical industry, Vaccine

Stonegate Healthcare's research approach centers on conducting a thorough comparative analysis to identify potentially revolutionary assets and technologies.

Key Points: 
  • Dallas, Texas--(Newsfile Corp. - July 13, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innovative advancements in RNA Therapeutics.
  • The report, The RNA Revolution: Unleashing the Therapeutic Potential of RNAi, highlights the potential of RNA therapeutics and companies leveraging RNAi technologies are in particular focus as we believe this will be a meaningful area of development.
  • The report covers over 30 companies, highlighted companies include Alnylam, Ionis, Laronde, TME Pharma, and Transcode Therapeutics (NASDAQ: RNAZ) among others.
  • The report covers the major areas of RNA therapeutics highlighting innovative and undervalued companies focused on developing RNAi, mRNA, and Aptamer technologies.

Basking Biosciences Presents Novel Reversible RNA-aptamer Thrombolytic at Locus Walk RNA Innovation Conference

Retrieved on: 
Tuesday, May 9, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Partnership, University of Massachusetts, Bleeding, Stroke, Toxicity, Brain, RNA, Willebrand, Von Willebrand factor, Blood, MRI, Patient, Thrombus, Beth Israel, Aptamer, Conference, Vaccine

Basking Biosciences (Basking), a clinical-stage biopharmaceutical company, today discussed the development status of BB-031, the company’s novel, RNA-based thrombolytic for use in patients experiencing acute ischemic stroke, at the Locus Walk RNA Innovation Conference, held virtually.

Key Points: 
  • Basking Biosciences (Basking), a clinical-stage biopharmaceutical company, today discussed the development status of BB-031, the company’s novel, RNA-based thrombolytic for use in patients experiencing acute ischemic stroke, at the Locus Walk RNA Innovation Conference, held virtually.
  • BB-031, a rapid onset, short-acting agent, is an RNA aptamer targeting von Willebrand Factor (vWF), a key structural component of thrombi and driver of blood clotting.
  • Uniquely, the thrombolytic activity of BB-031 is designed to be quickly neutralized in the event of bleeding using a complementary agent, BB-025, which Basking is developing in tandem.
  • “RNA aptamers have a number of characteristics that make them exceptionally well suited for treating acute thrombosis,” said Richard Shea, Chief Executive Officer of Basking.

MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology

Retrieved on: 
Wednesday, March 8, 2023
Immunotherapy, Stanford University, Literature, Bone marrow, Therapy, Laboratory, University of Pennsylvania, Oncology, SAB, BS, Memorial Sloan Kettering Cancer Center, Internal medicine, Patient, Pharmacology, Translation, MUC1, Fordham University, United States Air Force Scientific Advisory Board, MD, ETH Zurich, Massachusetts Institute of Technology, Harvard Medical School, Cell, History of the University of Maryland, College Park, University, Biosensor, Harvard University, Doctor of Philosophy, Glycosylation, Chromatin, NF-κB, LSE, Research, Hematology, CAR, Cell engineering, UMBC, Aptamer, Management, Vaccine, Biology, Genetics, Medicine, Chemistry, Biochemistry

“With the formation of our Scientific Advisory Board, we are expanding the depth and breadth of our leadership team and scientific expertise with the next generation of leaders in the field of gene and cell therapy,” said Doug Doerfler, President and CEO of MaxCyte.

Key Points: 
  • “With the formation of our Scientific Advisory Board, we are expanding the depth and breadth of our leadership team and scientific expertise with the next generation of leaders in the field of gene and cell therapy,” said Doug Doerfler, President and CEO of MaxCyte.
  • Supported by deep technical knowledge, the SAB will help us unlock the power of cells, which will enhance our R&D activities and portfolio,” said Cenk Sumen, PhD, Chief Scientific Officer of MaxCyte.
  • Dr. Maus holds graduate degrees (M.D., Ph.D.) from University of Pennsylvania, where she completed graduate training with Dr. Carl June.
  • Her thesis exploited aptamers to overcome the conventional bottlenecks of electronic biosensing of small molecules in complex biological environments.

ROSALIND FRANKLIN UNIVERSITY GRANTS TO TACKLE COMPLICATIONS OF HIV AND STEM CELL THERAPY FOR BRAIN REPAIR

Retrieved on: 
Thursday, March 2, 2023
Knowledge, Aptamer, Cancer, Disease, Multimedia, Engineering, Biology, Myenteric plexus, Research, Regenerative medicine, Intelligence, KSHV, Patient, Facial muscles, Science, Infection, Neuroscience, Illinois Institute of Technology, B cell, PEL, Rosalind Franklin University of Medicine and Science, Primary effusion lymphoma, Tissue, National Cancer Institute, Culture, Kaposi's sarcoma, RFU, Microbiology, Neuron, IIT, Mortality, Cell, Chemical engineering, Brain, Vaccine

NORTH CHICAGO, Ill., March 2, 2023 /PRNewswire/ -- New funding for Rosalind Franklin University researchers will help revolutionize therapeutic approaches for HIV-related cancers and for brain repair.

Key Points: 
  • NORTH CHICAGO, Ill., March 2, 2023 /PRNewswire/ -- New funding for Rosalind Franklin University researchers will help revolutionize therapeutic approaches for HIV-related cancers and for brain repair.
  • "KSHV, a human oncogenic herpesvirus, is the underlying cause of KS tumor (lesions) and a rare B cell malignancy called primary effusion lymphoma (PEL)," Dr. Sharma-Walia said.
  • "KS is the most common vascular malignancy causing high morbidity and mortality in HIV-infected patients."
  • ROSALIND FRANKLIN UNIVERSITY encompasses six colleges and more than 10 research centers and institutes.

Pusan National University Researchers Uncover Novel Gene That Regulates Leukemia Development and Progression

Retrieved on: 
Wednesday, February 1, 2023
B cell, AML, Mouse, Bone marrow, Hematological Cancer Research Investment and Education Act, Protein, Myeloid leukemia, Leukemia, ROS, Acute myeloid leukemia, Patient, Aptamer, Cell, RNA, SURF4, Research, Letter, TBK1, Cell death, STAT6, Immune system, Death, Differentiable function, Disease, Growth, Prevalence, Pusan National University, Neoplasm, Vaccine

BUSAN, South Korea, Feb. 1, 2023 /PRNewswire/ -- Leukemia, a type of blood cancer, affected around 2.3 million people around the world in 2015. Acute myeloid leukemia (AML)—a particularly aggressive disease—generally starts in the bone marrow, when stem cells cannot differentiate into white blood cells, which reduces the number of healthy blood cells in the body, leading to a very weak immune system, among other problems. Given the prevalence and implications of this disease, there has been a lot of research on the development and progression of leukemia. This has led to the discovery of a protein, stimulator of interferon genes (STING), which interacts with two other proteins—TANK-binding kinase 1 (TBK1) and signal transducer and activator of transcription 6 (STAT6)—to exert anti-cancer effects in blood cancers. Researchers have also observed that a particular gene—surfeit 4 (SURF4)—is highly expressed in leukemic cells, and its protein, SURF4, binds to STING. However, we are still unclear about how SURF4 affects the STING-TBK1-STAT6 axis, and what role it plays in leukemia. So, a team of researchers from Pusan National University, Republic of Korea set out to understand this. They were led by Professors Dongjun Lee and Yun Hak Kim, who explain the rather humanitarian motive for their research. "Children who suffer from AML relapses seldom survive. This makes studying the mechanisms of AML very important. Uncovering the effects of proteins like SURF4 may lead to new therapeutic strategies for AML, which hasn't happened in four decades". The team ran a series of experiments, the findings of which are detailed in a letter to the editor, published on 6 November 2022 in Cancer Communications.

Key Points: 
  • Given the prevalence and implications of this disease, there has been a lot of research on the development and progression of leukemia.
  • Researchers have also observed that a particular gene—surfeit 4 (SURF4)—is highly expressed in leukemic cells, and its protein, SURF4, binds to STING.
  • However, we are still unclear about how SURF4 affects the STING-TBK1-STAT6 axis, and what role it plays in leukemia.
  • So, a team of researchers from Pusan National University, Republic of Korea set out to understand this.

Aptamer Group Appointment of Interim Chief Commercial Officer

Retrieved on: 
Tuesday, January 10, 2023
Interim, AIM, Aptamer, Management

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the appointment of Derek Smith as Interim Chief Commercial Officer, effective as of 1st January 2023.

Key Points: 
  • Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the appointment of Derek Smith as Interim Chief Commercial Officer, effective as of 1st January 2023.
  • Prior to joining Aptamer Group, Derek held senior sales positions at various UK healthcare companies.
  • Derek’s commercial mindset and dedication to the business will stand him in good stead as Interim Chief Commercial Officer.
  • I look forward to working closely with him as we continue to pursue our strategic goals.”
    Derek Smith, Interim Chief Commercial Officer, said: “I’ve really enjoyed working at Aptamer over the past few years and being a part of its significant commercial progress, including playing a part in the Company’s public listing on AIM.

Achiko AG Commences Commercial Deliveries in Indonesia

Retrieved on: 
Monday, November 14, 2022
Hospital, Marketing, ISIN, ACHI, CE marking, Nanoparticle, Aptamer, NU, Nahdlatul Ulama, Gold, COVID-19, Union, LR, OTCQB, School, University, Vaccine, DKI

53 LR Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (Achiko, the Company) is proud to announce that following pilot production with manufacturing partner PT Indofarma Tbk, the Company is now commencing commercial deliveries of its Generation 2 AptameX Covid-19 test kit to Nahdlatul Ulama (NU) and other commercial clients, both starting in and around Jakarta.

Key Points: 
  • 53 LR Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (Achiko, the Company) is proud to announce that following pilot production with manufacturing partner PT Indofarma Tbk, the Company is now commencing commercial deliveries of its Generation 2 AptameX Covid-19 test kit to Nahdlatul Ulama (NU) and other commercial clients, both starting in and around Jakarta.
  • Were excited to commence commercial deliveries in Indonesia.
  • Achiko AG (SIX: ACHI.SW, OTCQB: ACHKF, www.achiko.com ) is developing disruptive diagnostic solutions that put people first.
  • Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of diseases in the rapidly evolving healthcare diagnostics field.

Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy

Retrieved on: 
Monday, September 19, 2022
Therapy, Degenerative disease, Gene silencing, Survivin, NR2F6, RNA transfection, Company, Gene, News, PINK, Immunotherapy, Forward-looking statement, Cancer, RNA, OTC, CEO, USPTO, Technology, Protein, Regulation, Checkpoint, Aptamer, SAN, DNA, PD-1, Patent, Pharmaceutical industry, Vaccine

SAN DIEGO, Sept. 19, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today filing of a provisional patent application with the USPTO entitled "Dual Checkpoint Inhibitor Aptamer Based Therapeutics". The application covers novel compositions of matter capable of acting as conventional checkpoint inhibitor drugs while simultaneously silencing genes which regulate T cells and cancer cells such as NR2F6 and Survivin.  The Company believes that this platform technology is the first combination of an immunotherapy and a gene silencing agent in a single drug. 

Key Points: 
  • The Company believes that this platform technology is the first combination of an immunotherapy and a gene silencing agent in a single drug.
  • Aptamers are short DNA or RNA sequences which can function as antibodies they recognize specific proteins and bind to them.
  • Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders.
  • Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.